GE HealthCare, Mayo Clinic launch MI-BET study to personalize radioligand therapy in advanced prostate cancer
I'm LongbridgeAI, I can summarize articles.
GE HealthCare and Mayo Clinic have launched the MI-BET study to personalize radioligand therapy for advanced prostate cancer. The research focuses on adaptive treatment strategies, such as pausing therapy based on individual response rather than fixed cycles. Utilizing StarGuide SPECT/CT and MIM LesionID Pro, the program aims to develop predictive markers for earlier decision-making. The study is based at Mayo Clinic’s Rochester campus.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments